Drug Discovery World

MARCH 14, 2023

Teitur Trophics, a biotech company developing new treatments for patients suffering from neurodegenerative diseases, has complete a €28M Series A financing. The financing was co-led by Sunstone Life Science Ventures and Sound Bioventures, with participation from new investors, Industrifonden, Innovestor’s Life Science Fund and P53 Invest.

Disease 130

Disease Treatment Science Clinical Development 130

Fierce BioTech

JULY 19, 2023

Accelerating time to treatment. Don't miss this opportunity to gain valuable insights and explore the future of clinical development. png Listing Introduction Join us for an engaging webinar that explores how innovative automation capabilities are transforming the landscape of clinical development in the life sciences industry.

Clinical Development 52

Clinical Development Science Pharmaceuticals Treatment 52

Drug Discovery World

SEPTEMBER 4, 2024

Evommune’s pre-clinical data demonstrates that by blocking activation of MRGPRX2 via all disease relevant ligand categories, EVO756 can prevent the degranulation of mast cells. “As we continue to execute on our clinical development plans for EVO756, we are commencing this Phase II trial in 15 study sites across the United States.

Clinical Trials 130

Clinical Trials Trials Small Molecule Clinical Development 130

Drug Discovery World

JUNE 6, 2023

BenevolentAI, developers of AI that accelerates biopharma discovery, has delivered BEN-34712, its pre-clinical candidate for the potential treatment of amyotrophic lateral sclerosis (ALS). ” The post BenevolentAI progresses drug for the potential treatment of ALS appeared first on Drug Discovery World (DDW).

Treatment 130

Treatment Drugs Clinical Development Therapies 130

Drug Discovery World

SEPTEMBER 14, 2023

6,7 “For patients with advanced UC, including FGFR-driven tumours, outcomes remain poor and treatment options are limited; therefore, there is a need for novel, targeted therapies,” said Martin Vogel, EMEA Therapeutic Area Lead Oncology, Janssen-Cilag GmbH. “We Erdafitinib for the treatment of metastatic bladder cancer. J Clin Med.

Treatment 130

Treatment Clinical Pharmacology FDA Approval Therapies 130

Drug Discovery World

OCTOBER 11, 2022

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved a new class of treatment for adults with insufficiently controlled type 2 diabetes. . It is the first GIP and GLP-1 receptor agonist authorised for the treatment of adults with type 2 diabetes in Great Britain. .

Treatment 130

Treatment Clinical Development Production Marketing 130

Drug Target Review

JUNE 9, 2023

This exclusive interview with Dr Sharon Benzeno, Chief Commercial Officer, Immune Medicine at Adaptive Biotechnologies, unveils some ground-breaking research on T- cell therapy for cancer , which has seen the first TCR-based therapeutic candidate progress to clinical development, offering promising advancements in innovative cancer treatments.

Treatment 105

Treatment Packaging Clinical Research Therapies 105

Drug Target Review

OCTOBER 11, 2023

More than 7,000 rare diseases – conditions that affect fewer than 1 in 2,000 people – have been identified, and1 in 17 people will develop a rare disease in their lifetime, with children disproportionately affected. Most of these conditions are genetic in origin and the majority have no effective treatment.

Disease 113

Disease Treatment Small Molecule Therapies 113

The Pharma Data

DECEMBER 14, 2020

AlgoTherapeutix recently raised a 12M€ Series A that will fund the Phase 1 and 2 clinical development of ATX01. About AlgoTherapeutix AlgoTx was founded in 2018 by Stéphane Thiroloix and Olivier Bohuon to develop topical treatments for complex pain and was incubated by Paris Biotech Santé. 15, 2020 07:15 UTC.

Clinical Development 52

Clinical Development Clinical Supply Pharmacokinetics Packaging 52

Drug Discovery World

SEPTEMBER 6, 2024

Vincent Carrère, CEO of NH TherAguix, added: “This first positive step paves the way for the major next inflexion point expected in the second half of the year regarding the interim efficacy analysis of AGuIX.

Trials 130

Trials Clinical Trials Clinical Development Hospitals 130

Drug Discovery World

JUNE 26, 2024

“NDO is a serious bladder condition, for whom treatment options are limited,” said Cornelia Haag-Molkenteller, Chief Medical Officer of EG 427. These data have shown that one course of treatment with EG110A can potentially lead to long-lasting efficacy without affecting the bladder function.”

Therapies 148

Therapies Clinical Development Disease FDA 148

Drug Discovery World

JULY 12, 2024

The US Food and Drug Administration (FDA) has granted Fast Track Designation for Asklepios BioPharmaceutical’s (AskBio) AB-1005 which is being developed for moderate Parkinson’s disease. AB-1005 is an investigational adeno-associated virus 2 glial cell line-derived neurotrophic factor (AAV2-GDNF) neurorestorative gene therapy.

Therapies 148

Therapies Clinical Trials FDA Clinical Development 148

Drug Discovery World

DECEMBER 5, 2023

Cancer Research UK (CRUK), Cancer Research Horizons, and precision oncology company Guardant Health have launched a collaboration to advance cancer treatment. This includes the DETERMINE trial – the first UK national precision medicine trial in rare cancers, and other CRUK and Cancer Research Horizons research collaborations.

Clinical Trials 287

Clinical Trials Drugs Trials Clinical Development 287

Drug Discovery World

APRIL 18, 2023

billion by 2026, these drugs are primarily indicated for the treatment of multiple myeloma. AVA3996 is in pre-clinical development with the aim of submitting an Investigational New Drug (IND) application to allow clinical development to begin during 2024.

Therapies 242

Therapies Clinical Development Treatment Marketing 242

Drug Discovery World

JULY 5, 2024

Newron Pharmaceuticals has reported new findings of mechanism of action that indicate its drug candidate evenamide could be uniquely effective in patients with treatment resistant schizophrenia (TRS).

Pharmaceuticals 265

Pharmaceuticals Clinical Development International Therapies 265

Drug Discovery World

MARCH 10, 2023

Cancer Research UK and UCB have agreed a clinical development collaboration to advance two of UCB’s investigational oncology antibody candidates through clinical trials. If successful in clinical trials the investigational candidates may have the potential to offer cancer patients access to new targeted treatment options.

Research 246

Research Clinical Trials Clinical Development Trials 246

Drug Discovery World

AUGUST 21, 2024

TF is a clinically validated ADC target that is highly expressed in indications such as non-small cell lung cancer, colorectal cancer, cervical cancer, oesophageal cancer, head and neck cancer, bladder cancer and certain gastrointestinal cancers, but its expression is limited in normal tissues.

Licensing 130

Licensing Licensing Clinical Development Clinical Trials 130

Drug Discovery World

FEBRUARY 26, 2024

The US Food and Drug Administration (FDA) has granted Fast Track Designation for Certa Therapeutics’ investigational therapy FT011 for the treatment of systemic sclerosis (scleroderma). The post Scleroderma drug gets fast-tracked in the US appeared first on Drug Discovery World (DDW).

Clinical Trials 130

Clinical Trials Drugs Therapies FDA 130

Drug Discovery World

JULY 5, 2024

People living with FTD-GRN have no available disease-modifying treatments and the impact of this disorder is profound for both patients and their families,” said Dr James ‘Brad’ Elder, Professor of Neurological Surgery at The Ohio State University Wexner Medical Center.

Therapies 148

Therapies Trials Clinical Trials Clinical Development 148

Drug Discovery World

FEBRUARY 27, 2024

The results support the continued clinical development of VXX-401 as a candidate for the treatment of hypercholesterolemia and prevention of atherosclerotic cardiovascular disease. New studies have demonstrated that Vaxxinity’s vaccine VXX-401 reproducibly lowers low-density lipoprotein cholesterol (LDL-C) in non-human primates.

Vaccine 261

Vaccine Clinical Trials Disease Clinical Development 261

Drug Discovery World

SEPTEMBER 5, 2023

BenevolentAI has dosed the first patients in Phase I first-in-human studies of its oral phosphodiesterase 10 (PDE10) inhibitor, BEN-8744, intended for the treatment of ulcerative colitis (UC). The topline data readout from this study is expected in the first quarter of 2024.

Treatment 148

Treatment Clinical Development Disease Drugs 148

Drug Discovery World

MARCH 7, 2024

It has potential to be the first approved treatment for HSCT-TMA, a rare complication of stem cell transplantation that has an 80% mortality rate among severe adult and paediatric patients. Akari’s long-acting version of nomacopan (PASylated-nomacopan) is in the final stages of pre-clinical development for geographic atrophy (GA).

Clinical Trials 148

Clinical Trials Licensing Licensing Clinical Development 148

Drug Discovery World

APRIL 17, 2024

Under the terms of the transaction agreements, Novartis will be responsible for worldwide clinical development and commercialisation of ARV-766 and will have all research, development, manufacturing, and commercialisation rights with respect to the preclinical AR-V7 programme. “We

Licensing 130

Licensing Licensing Clinical Development Treatment 130

Drug Discovery World

NOVEMBER 30, 2023

Treatment with FT011 for 12 weeks resulted in a clinically meaningful improvement in 60% of patients treated with FT011 400mg and 20% of patients in the FT011 200mg group compared with 10% in the placebo group. I look forward to collaborating with the company in the FT011 development program ahead.”

Drug Trials 148

Drug Trials Trials Clinical Trials Drugs 148

Drug Discovery World

JANUARY 25, 2024

The US Food and Drug Administration (FDA) has granted Orphan Drug Designation to Pleco Therapeutics’s lead compound PTX-252 for the treatment of acute myeloid leukaemia (AML). PTX-252 is a novel molecular entity developed to increase the sensitivity of cancer cells to chemotherapy.

FDA 130

FDA Drugs Clinical Trials Clinical Development 130

Drug Discovery World

OCTOBER 14, 2022

“We have been collaborating with Merck on PCVs since 2016, and together we have made significant progress in advancing mRNA-4157 as an investigational personalised cancer treatment used in combination with KEYTRUDA,” said Stephen Hoge, President of Moderna.

Vaccine 244

Vaccine Research Laboratories Laboratories Clinical Development 244

Drug Discovery World

MAY 23, 2024

AltruBio has closed an oversubscribed Series B financing of up to $225 million, which will be used to advance the clinical development of the first-in-class, novel immune checkpoint enhancer (ICE) PSGL-1 agonist antibody, ALTB-268. This study is anticipated to read out in 2H of 2026.

Clinical Trials 130

Clinical Trials Trials Clinical Development Treatment 130

Drug Discovery World

JUNE 6, 2024

months after initial treatment. Ultimately it will contribute to survival rates improving continually over the next decades and more.” The follow-up of the Phase IIb study took place 34.9 It showed that the 2.5-year year recurrence-free survival rate of mRNA-4157 with Keytruda was 74.8% compared to 55.6% for Keytruda alone.

Vaccine 148

Vaccine Clinical Trials FDA Approval Research Laboratories 148

Drug Discovery World

MAY 29, 2024

All 11 trial participants had experienced disease progression in prior immunotherapy treatment before joining the trial. These preliminary findings represent some of the initial positive evidence emerging from the burgeoning field of clinical research on cancer therapies leveraging gut microbiota.

Trials 130

Trials Clinical Trials Treatment Clinical Development 130

Drug Discovery World

APRIL 12, 2024

Daiichi Sankyo and AstraZeneca’s Enhertu (fam-trastuzumab deruxtecan-nxki) has been approved in the US for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumours. In DESTINY-PanTumor02, overall response rate (ORR) was 51.4% and median duration of response (DOR) range was 19.4

Clinical Trials 130

Clinical Trials Trials Engineering FDA 130

The Pharma Data

SEPTEMBER 29, 2021

to enhance outcomes, new treatments which will target kidney-specific disease mechanisms are highly desired,” said Hiddo L. Christian Rommel, Member of the chief Committee of Bayer AG’s Pharmaceutical Division and Head of Research and Development.

Clinical Development 52

Clinical Development Disease Clinical Trials Trials 52

Covalent Modifiers

MAY 9, 2024

BIIB129 (25) demonstrated efficacy in disease-relevant preclinical in vivo models of B cell proliferation in the CNS, exhibits a favorable safety profile suitable for clinical development as an immunomodulating therapy for MS, and has a low projected total human daily dose.

Treatment 77

Treatment Clinical Development Regulations Disease 77

Drug Discovery World

MARCH 15, 2024

We are excited to begin the next phase of development with the initiation of two 28-day patient studies, the first studies of ALX-001 in people living with Alzheimer’s and Parkinson’s disease,” commented Tim Siegert, Chief Operating Officer and Co-Founder of Allyx Therapeutics. “We

Disease 130

Disease Trials Small Molecule Pharmacokinetics 130

Drug Discovery World

JANUARY 10, 2024

The acquisition includes Aiolos’ AIO-001, a potentially best-in-class, long-acting anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody ready to enter Phase II clinical development for asthma, with potential for additional indications.

Pharmacokinetics 130

Pharmacokinetics Licensing Licensing Clinical Development 130

Drug Discovery World

MARCH 26, 2024

DDW’s Megan Thomas caught up with Oliver Rausch, Chief Scientific Officer at Storm Therapeutics, following the ESMO Targeted Anticancer Therapies Congress 2024, a global meeting focusing on promising new anticancer targets and agents, focusing on those in early phase clinical development.

Therapies 163

Therapies Small Molecule RNA DNA 163

Drug Discovery World

JULY 3, 2023

Janssen has announced positive results from the proof-of-concept Phase II UNITY trial for the treatment of pregnant individuals at high risk of early-onset severe (EOS) haemolytic disease of the foetus and newborn (HDFN). The post Janssen reveals positive trial data for nipocalimab appeared first on Drug Discovery World (DDW).

Trials 130

Trials Medical Schools Clinical Development Treatment 130

Drug Discovery World

MARCH 18, 2024

In the five JNJ-2113 treatment groups, as measured by the Psoriasis Area and Severity Index (PASI), response rates were maintained from Week 16 to Week 52, with the highest PASI 75 response observed in the 100mg twice daily group.

Clinical Trials 130

Clinical Trials Drugs Trials Clinical Development 130